Table 1.

Clinical features of patients with dermatomyositis and controls. Data are mean ± SD unless otherwise indicated.

Clinical FeaturesPatients, n = 51Controls, n = 51
Age, yrs44.06 ± 11.8044.41 ± 10.60
Female, %84.3184.31
Duration, mos (range)8 (0.3, 48)
DAS score (range)10 (5, 17)
Muscle weakness, %100
Myalgia, %28.41
Polyarthralgia, %35.29
Heliotrope rash, %64.71
Gottron sign, %60.78
Shawl sign, %17.65
Raynaud phenomenon, %7.84
Lung involvement, %52.940
Systolic BP, mmHg117.61 ± 11.57118.67 ± 10.03
Diastolic BP, mmHg72.14 ± 12.9374.76 ± 7.27
Heart rate, beats/min81.35 ± 6.7480.10 ± 4.13
Triglyceride, mmol/l1.68 ± 0.771.36 ± 0.79*
Total cholesterol, mmol/l4.79 ± 1.234.77 ± 0.70
LDL cholesterol, mmol/l2.85 ± 1.212.71 ± 0.66
HDL cholesterol, mmol/l1.44 ± 0.451.54 ± 0.34
Serum uric acid, umol/l306.49 ± 95.38330.20 ± 93.52
Fasting plasma glucose, mmol/l4.78 ± 0.794.84 ± 0.67
ANA-positive, %84.310
Anti-Jo1 antibody-positive, %9.800
Medications, %
  Glucocorticoid94.110
  Methotrexate25.490
  Azathioprine3.920
  Cyclophosphamide21.570
  Hydroxychloroquine58.820
  IVIG00
  Biologics00
  • p < 0.05. DAS: Disease Activity Score; BP: blood pressure; LDL: low-density lipoprotein; HDL: high-density lipoprotein; IVIG: intravenous immunoglobulin; ANA: antinuclear antibody.